|
Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
|
May 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study
|
Dec 2015
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia
|
Jan 2014
|
Am J Hematol
|
aplastic anemia
|
|
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes
|
Mar 2013
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival
|
Dec 2014
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Costs and quality of life in patients with myelodysplastic syndromes.
|
Aug 2013
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Quality of life and physicians' perception in myelodysplastic syndromes
|
May 2012
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
|
Jul 2020
|
Aging
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
|
Jun 2023
|
Advances in Therapy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
